Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

Apr 19, 2022

SELL
$58.27 - $118.99 $12,528 - $25,582
-215 Closed
0 $0
Q4 2021

Jan 27, 2022

BUY
$100.76 - $138.36 $21,663 - $29,747
215 New
215 $25,000

Others Institutions Holding NTLA

About Intellia Therapeutics, Inc.


  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $1.06B
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Paragon Capital Management LTD Portfolio

Follow Paragon Capital Management LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Paragon Capital Management LTD, based on Form 13F filings with the SEC.

News

Stay updated on Paragon Capital Management LTD with notifications on news.